

Avelumab in patients with chemotherapy-refractory m
multicentre, single-group, open-label, phase 2 trial

Lancet Oncology, The
17, 1374-1385

DOI: [10.1016/s1470-2045\(16\)30364-3](https://doi.org/10.1016/s1470-2045(16)30364-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Metastatic Merkel cell carcinoma response to nivolumab. , 2016, 4, 79.		40
2	Merkel Cell Carcinoma: Characteristics, Management, and What's on the Horizon. Clinical Skin Cancer, 2016, 1, 66-74.	0.1	1
3	Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma?. Lancet Oncology, The, 2016, 17, 1337-1339.	5.1	14
4	Avelumab effective against Merkel-cell carcinoma. Nature Reviews Clinical Oncology, 2016, 13, 652-652.	12.5	6
5	Embracing a Standard of Care for Merkel Cell Carcinoma With Immunotherapy. Clinical Skin Cancer, 2016, 1, 53-56.	0.1	0
6	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1341-1367.	0.8	318
7	Novel immune check point inhibiting antibodies in cancer therapyâ€”Opportunities and challenges. Drug Resistance Updates, 2017, 30, 39-47.	6.5	98
8	Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists. Expert Review of Anticancer Therapy, 2017, 17, 281-287.	1.1	8
10	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. , 2017, 5, 20.		78
11	Let This Be Our New Year's Pledge. Oncologist, 2017, 22, 1-2.	1.9	42
12	Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opinion on Biological Therapy, 2017, 17, 515-523.	1.4	60
13	Novel immune checkpoint blocker to treat Merkel cell carcinoma. Oncoimmunology, 2017, 6, e1315496.	2.1	1
14	Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. Annals of Oncology, 2017, 28, 1658-1666.	0.6	26
15	Emerging therapies for breast cancer. Journal of Hematology and Oncology, 2017, 10, 98.	6.9	60
16	ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. International Journal of Cancer, 2017, 141, 583-593.	2.3	37
17	Avelumab: First Global Approval. Drugs, 2017, 77, 929-937.	4.9	98
18	New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Current Opinion in Oncology, 2017, 29, 221-226.	1.1	42
19	Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Scientific Reports, 2017, 7, 2290.	1.6	99

#	ARTICLE	IF	CITATIONS
20	Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases. <i>JAAD Case Reports</i> , 2017, 3, 185-189.	0.4	31
21	Clinical applications of PD-L1 bioassays for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 110.	6.9	66
22	Skin Cancers in Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 2509-2530.	2.6	151
23	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 647-655.	1.1	14
24	Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. <i>Future Oncology</i> , 2017, 13, 1699-1710.	1.1	98
25	Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. <i>European Journal of Cancer</i> , 2017, 77, 84-87.	1.3	42
26	Diagnosis and Treatment of Kaposi Sarcoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 529-539.	3.3	98
27	Seeking Standards for the Detection of Merkel Cell Polyomavirus and its Clinical Significance. <i>Journal of Investigative Dermatology</i> , 2017, 137, 797-799.	0.3	12
28	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 1263-1279.	1.1	113
29	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology</i> , The, 2017, 18, 587-598.	5.1	261
30	Antibodies to watch in 2017. <i>MAbs</i> , 2017, 9, 167-181.	2.6	225
31	Role of FcγR interactions in the antitumor activity of therapeutic antibodies. <i>Immunology and Cell Biology</i> , 2017, 95, 340-346.	1.0	35
32	Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. <i>European Journal of Cancer</i> , 2017, 71, 53-69.	1.3	307
33	Clinical trials of CAR-T cells in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 166.	6.9	62
34	Merkel cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17077.	18.1	393
36	Concurrent Merkel Cell Carcinoma and Melanoma in Individual Patients Presents a Treatment Challenge: A Case Series. <i>Clinical Skin Cancer</i> , 2017, 2, 69-72.	0.1	1
37	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 1-12.	2.0	141
38	The evolutionary nature of the cancer immunotherapy revolution. <i>Future Oncology</i> , 2017, 13, 1565-1567.	1.1	4

#	ARTICLE	IF	CITATIONS
39	Avelumab and other recent advances in Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 2771-2783.	1.1	11
40	Reply to "Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma". <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1537-1537.	0.9	0
41	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. <i>Drug Resistance Updates</i> , 2017, 32, 1-15.	6.5	132
42	Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2157-2162.	0.5	12
43	Advances in Merkel cell carcinoma from a pathologist's perspective. <i>Pathology</i> , 2017, 49, 568-574.	0.3	16
44	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Oncolmmunology</i> , 2017, 6, e1373237.	2.1	62
45	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of 2 patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1080-1086.	0.7	48
46	Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 517-532.	2.6	41
47	Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S26-S42.	1.0	91
48	T cell therapies for human polyomavirus diseases. <i>Cytotherapy</i> , 2017, 19, 1302-1316.	0.3	17
49	PD-1 checkpoint inhibition: Toxicities and management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 701-707.	0.8	57
50	Merkel cell polyomavirus and Merkel cell carcinoma. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160276.	1.8	78
51	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. <i>Immunotherapy</i> , 2017, 9, 797-804.	1.0	30
52	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1338237.	2.1	47
53	Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way. <i>Pharmacogenomics</i> , 2017, 18, 1299-1304.	0.6	4
54	Preclinical evaluation of NF- κ B-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 451-464.	1.4	18
55	Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment. <i>Annals of Surgical Oncology</i> , 2017, 24, 3430-3437.	0.7	24
56	Kidney Toxicities Associated With Novel Cancer Therapies. <i>Advances in Chronic Kidney Disease</i> , 2017, 24, 233-240.	0.6	14

#	ARTICLE	IF	CITATIONS
57	Immunosuppressive Agents and Their Role in Managing Immunotherapy Toxicities in Melanoma. <i>Clinical Skin Cancer</i> , 2017, 2, 18-23.	0.1	5
58	Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 791-805.	1.0	4
59	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	1.8	106
60	Targeting immune checkpoints in breast cancer: an update of early results. <i>ESMO Open</i> , 2017, 2, e000255.	2.0	118
61	PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 937-939.	1.5	17
62	De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology</i> , The, 2017, 18, e731-e741.	5.1	568
63	Drug Monographs: Avelumab and Ribociclib. <i>Hospital Pharmacy</i> , 2017, 52, 459-463.	0.4	0
65	Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 969-973.	0.4	3
66	Combination Therapy with NHS-muLL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. <i>Clinical Cancer Research</i> , 2017, 23, 5869-5880.	3.2	52
67	Update on Merkel Cell Carcinoma. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 485-501.	0.7	67
68	Endocrine dysfunction following immune checkpoint inhibitor therapy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 337-347.	1.2	18
69	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. <i>European Respiratory Review</i> , 2017, 26, 170007.	3.0	74
72	Clinical use of immune checkpoint inhibitors. , 2017, , .		0
73	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2017, 8, 730.	1.6	350
74	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 51-71.	2.7	101
75	Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 73-82.	2.7	121
76	Viral Oncology: Molecular Biology and Pathogenesis. <i>Journal of Clinical Medicine</i> , 2017, 6, 111.	1.0	118
77	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225

#	ARTICLE	IF	CITATIONS
78	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. <i>Frontiers in Immunology</i> , 2017, 8, 961.	2.2	93
79	CD80 Expressed by CD8 ⁺ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8 ⁺ T Cells. <i>Journal of Immunology Research</i> , 2017, 2017, 1-6.	0.9	33
80	Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4803-4807.	1.0	14
81	Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1252-1254.	0.6	3
82	Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 247.	1.0	14
83	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 174.	6.9	92
84	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37
85	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
88	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	44
89	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 641-650.	1.8	9
90	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. <i>Oncotarget</i> , 2017, 8, 106132-106142.	0.8	174
91	Avelumab—a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, S35-S38.	1.3	6
92	Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, S41-S43.	1.3	2
93	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	57
94	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers. <i>JAMA Oncology</i> , 2018, 4, 522.	3.4	92
95	Biopsy-Proven Metastatic Merkel Cell Carcinoma to the Orbit: Case Report and Review of Literature. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, e86-e88.	0.4	8
96	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. <i>Cancer</i> , 2018, 124, 2010-2017.	2.0	81
97	Nivolumab combined with ruxolitinib: antagonism or synergy?. <i>Annals of Oncology</i> , 2018, 29, 1334-1335.	0.6	11

#	ARTICLE	IF	CITATIONS
98	PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. Expert Review of Clinical Pharmacology, 2018, 11, 345-359.	1.3	27
99	Avelumab: a new standard for treating metastatic Merkel cell carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 319-326.	1.1	23
100	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist, 2018, 23, 814-821.	1.9	30
101	Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clinical Cancer Research, 2018, 24, 3644-3655.	3.2	18
102	Checkpoint-Inhibitor nun auch zur Therapie des metastasierten Merkelzellkarzinoms zugelassen. JDDG - Journal of the German Society of Dermatology, 2018, 16, 394-395.	0.4	1
103	Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma. Annals of Pharmacotherapy, 2018, 52, 928-935.	0.9	10
104	Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head and Neck, 2018, 40, 1676-1684.	0.9	9
105	Clinical assessment of immune-related adverse events. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876462.	1.4	101
106	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Review of Clinical Pharmacology, 2018, 11, 475-486.	1.3	83
108	Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Current Neurology and Neuroscience Reports, 2018, 18, 3.	2.0	83
109	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology, 2018, 7, e1433982.	2.1	38
110	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual Review of Medicine, 2018, 69, 301-318.	5.0	432
111	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. Targeted Oncology, 2018, 13, 1-20.	1.7	31
112	PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. Endocrine Pathology, 2018, 29, 59-67.	5.2	43
113	Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy, 2018, 10, 171-175.	1.0	21
114	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774974.	1.4	200
115	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF- β 2. Science Translational Medicine, 2018, 10, .	5.8	386
116	Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 365-369.	1.8	88

#	ARTICLE	IF	CITATIONS
117	Reprint of: Virus-Specific T Cells: Broadening Applicability. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S1-S6.	2.0	7
118	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncology</i> , The, 2018, 19, 416-426.	5.1	517
119	M7824, a novel bifunctional anti-PD-L1/TGF β 2 Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. <i>Oncolimmunology</i> , 2018, 7, e1426519.	2.1	162
120	CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 9-20.	3.8	100
121	Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2018, 14, 255-266.	1.1	22
122	PD-1/PD-L1 in disease. <i>Immunotherapy</i> , 2018, 10, 149-160.	1.0	90
123	Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 457-463.e2.	0.6	346
124	Merkel cell carcinoma: An update and review. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 445-454.	0.6	90
125	Merkel cell carcinomas infiltrated with CD33 + myeloid cells and CD8 + T cells are associated with improved outcome. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 973-982.e8.	0.6	33
126	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. <i>JAMA Oncology</i> , 2018, 4, 326.	3.4	43
127	A Woman With a Large Ulcerated Nodule on the Finger. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 78.	3.8	1
128	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	1.9	23
129	Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. <i>Clinical Cancer Research</i> , 2018, 24, 963-971.	3.2	57
130	Adjuvant radiation therapy improves patient survival in early-stage merkel cell carcinoma: A 15-year single-institution study. <i>Laryngoscope</i> , 2018, 128, 1862-1866.	1.1	15
131	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
132	Are there multiple cells of origin of Merkel cell carcinoma?. <i>Oncogene</i> , 2018, 37, 1409-1416.	2.6	84
133	Antibodies to watch in 2018. <i>MAbs</i> , 2018, 10, 183-203.	2.6	223
134	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF β 2, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1287-1295.	3.2	304

#	ARTICLE	IF	CITATIONS
135	The Basics of Cancer Immunotherapy. , 2018, , .		5
136	Immunotherapy for Other Malignancies. , 2018, , 125-142.		0
137	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
138	A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. <i>OncImmunology</i> , 2018, 7, e1466016.	2.1	42
139	CHECKPOINT INHIBITOR IMMUNE THERAPY. <i>Retina</i> , 2018, 38, 1063-1078.	1.0	252
140	Immune checkpoint blockade therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1403-1414.	1.5	79
141	Pseudoprogression and hyperprogression after checkpoint blockade. <i>International Immunopharmacology</i> , 2018, 58, 125-135.	1.7	121
142	Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design. <i>Future Oncology</i> , 2018, 14, 2103-2113.	1.1	63
143	Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1816-1823.	3.2	190
144	Update on Merkel Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 31-43.	1.3	30
145	Regulation and Function of the PD-L1 Checkpoint. <i>Immunity</i> , 2018, 48, 434-452.	6.6	1,437
146	An overview of the toxicities of checkpoint inhibitors in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 451-458.	0.5	19
147	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e180077.	3.4	304
148	Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences. <i>Patient</i> , 2018, 11, 439-449.	1.1	9
149	Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4. <i>Biochemistry and Biophysics Reports</i> , 2018, 13, 123-128.	0.7	4
150	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 408-419.	1.2	70
151	Toxicity profiles of immunotherapy. , 2018, 181, 91-100.		55
152	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. <i>Annals of Oncology</i> , 2018, 29, 71-83.	0.6	253

#	ARTICLE	IF	CITATIONS
153	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 141-154.	1.5	47
154	Virus-Specific T Cells: Broadening Applicability. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 13-18.	2.0	37
155	The application and mechanism of PD pathway blockade for cancer therapy. <i>Postgraduate Medical Journal</i> , 2018, 94, 53-60.	0.9	10
156	PD-L1 inhibitors in the pipeline: Promise and progress. <i>Oncolmunology</i> , 2018, 7, e1365209.	2.1	37
157	Dermatological Complications After Solid Organ Transplantation. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 185-212.	2.9	42
158	Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEK. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 341-351.	2.0	88
159	Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 2035-2043.	3.2	75
160	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
161	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 51-64.	5.1	491
162	Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1785-1794.	3.2	42
163	Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 178-188.	1.6	121
164	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0
165	Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 671-686.	1.1	564
166	Anti-PD-L1/TGF β 2R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 93.e1-93.e11.	0.8	40
168	Pharmacokinetics and Pharmacodynamics of Immunotherapy. <i>Current Cancer Research</i> , 2018, , 29-67.	0.2	6
169	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57
170	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 1260-1270.	3.2	289
171	Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. <i>Immunology Letters</i> , 2018, 193, 1-10.	1.1	13

#	ARTICLE	IF	CITATIONS
172	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 1020-1044.	0.8	108
173	Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America. <i>Journal of Global Oncology</i> , 2018, 4, 1-11.	0.5	5
174	Immunotherapy in treatment naïve advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S412-S421.	0.6	13
175	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	1.3	152
176	Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma. <i>Critical Reviews in Immunology</i> , 2018, 38, 159-206.	1.0	8
178	18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study. <i>EJNMMI Research</i> , 2018, 8, 64.	1.1	28
181	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018, 10, 1303-1313.	1.0	3
182	Aktuelle Therapiestudien beim Merkelzellkarzinom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1403-1404.	0.4	0
184	Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. <i>Current Oncology</i> , 2018, 25, 373-384.	0.9	109
185	Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. <i>Journal of Dermatological Science</i> , 2018, 92, 230-236.	1.0	11
186	Current Options and Future Directions in Immune Therapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 578.	1.3	21
187	Progress of immune checkpoint therapy in the clinic (Review). <i>Oncology Reports</i> , 2019, 41, 3-14.	1.2	24
188	Updates on Immunotherapy for the Treatment of Skin Cancer. <i>Current Dermatology Reports</i> , 2018, 7, 311-320.	1.1	2
189	Lethal thrombocytopenia in a patient treated with avelumab for metastatic Merkel cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 17, 73-75.	0.4	7
190	Development of PARP and Immune-Checkpoint Inhibitor Combinations. <i>Cancer Research</i> , 2018, 78, 6717-6725.	0.4	155
191	Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. <i>JAAD Case Reports</i> , 2018, 4, 1004-1006.	0.4	16
192	Neuroendocrine Key Regulator Gene Expression in Merkel Cell Carcinoma. <i>Neoplasia</i> , 2018, 20, 1227-1235.	2.3	16
193	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35

#	ARTICLE	IF	CITATIONS
194	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 351.	1.3	71
195	Immunotherapy for Merkel Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 57.	1.3	12
196	The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 763-776.	12.5	219
197	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2018, 15, 116.	1.4	52
198	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
199	Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. <i>Nature Communications</i> , 2018, 9, 3868.	5.8	211
201	On the Road to Immunotherapyâ€”Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2182.	2.2	15
202	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. <i>Genome Medicine</i> , 2018, 10, 79.	3.6	36
203	A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. <i>BMC Cancer</i> , 2018, 18, 1024.	1.1	3
204	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. , 2018, 6, 111.		122
205	Radiation Therapy in Merkel Cell Carcinoma. , 2018, , 1-20.		1
206	Treatment of metastatic nonâ€”small cell lung cancer with NYâ€”ESOâ€”1 specific TCR engineeredâ€”T cells in a phase I clinical trial: A case report. <i>Oncology Letters</i> , 2018, 16, 6998-7007.	0.8	29
207	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2018, 9, 8706-8715.	0.8	75
208	Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. <i>Antibody Therapeutics</i> , 2018, 1, 65-73.	1.2	25
209	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 7-16.	1.3	63
210	Immune-based therapeutic approaches to virus-associated cancers. <i>Current Opinion in Virology</i> , 2018, 32, 24-29.	2.6	4
211	Cellular sheddases are induced by Merkel cell polyomavirus small tumour antigen to mediate cell dissociation and invasiveness. <i>PLoS Pathogens</i> , 2018, 14, e1007276.	2.1	24
212	Merkel Cell Carcinoma: Updates on Pathogenesis, Diagnosis, and Management. <i>Current Dermatology Reports</i> , 2018, 7, 158-168.	1.1	0

#	ARTICLE	IF	CITATIONS
213	Impact of PD-L1, transforming growth factor- β expression and tumor-infiltrating CD8 ⁺ T cells on clinical outcome of patients with advanced thymic epithelial tumors. <i>Thoracic Cancer</i> , 2018, 9, 1341-1353.	0.8	20
214	Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 1-14.	2.7	34
215	Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 330-339.	0.4	28
216	Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. <i>PLoS ONE</i> , 2018, 13, e0203406.	1.1	1
217	Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1209-1219.	2.0	9
218	Avelumab: A Review in Metastatic Merkel Cell Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 409-416.	1.7	27
219	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 460-472.	0.6	14
220	Merkel cell carcinoma: Clinical outcome and prognostic factors in 351 patients. <i>Journal of Surgical Oncology</i> , 2018, 117, 1768-1775.	0.8	36
221	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. <i>Oncologist</i> , 2018, 23, 1171-1177.	1.9	29
222	Potential of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1381-1391.	2.0	25
223	Avelumab: is it time to get excited?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 815-821.	1.1	6
224	T Lymphocyte-Based Cancer Immunotherapeutics. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 201-276.	1.6	22
225	Merkel Cell Carcinoma Masquerading As Cellulitis: A Case Report and Review of the Literature. <i>Current Oncology</i> , 2018, 25, 106-112.	0.9	1
226	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. <i>Current Urology Reports</i> , 2018, 19, 68.	1.0	12
227	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5873-5882.	3.2	45
228	Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. <i>Annals of Internal Medicine</i> , 2018, 168, 121.	2.0	341
229	Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. <i>Frontiers in Immunology</i> , 2018, 9, 1614.	2.2	23
230	High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1475874.	2.1	20

#	ARTICLE	IF	CITATIONS
231	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. <i>Diagnostic Pathology</i> , 2018, 13, 47.	0.9	29
232	In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. , 2018, 6, 43.		37
233	Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. , 2018, 6, 58.		48
234	Predictors of survival in neurometastatic Merkel cell carcinoma. <i>European Journal of Cancer</i> , 2018, 101, 152-159.	1.3	10
235	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. <i>Targeted Oncology</i> , 2018, 13, 567-582.	1.7	12
236	How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 95.	1.2	13
237	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 374.	2.2	51
238	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatmentâ€™A Review From the Melanoma Perspective and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1474.	2.2	174
239	Merkel Cell Carcinoma: An Update and Immunotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 48.	1.3	40
240	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
241	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
242	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2018, 10, 32.	1.7	54
243	Update on Immunohistochemistry for the Diagnosis of Lung Cancer. <i>Cancers</i> , 2018, 10, 72.	1.7	94
244	Nanoparticleâ€™based photothermal and photodynamic immunotherapy for tumor treatment. <i>International Journal of Cancer</i> , 2018, 143, 3050-3060.	2.3	171
245	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2018, 62, 29-39.	1.7	860
247	The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 747.	1.8	42
248	MicroRNAs as Potential Biomarkers in Merkel Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1873.	1.8	17
249	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 999-1005.	2.3	15

#	ARTICLE	IF	CITATIONS
252	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
253	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
254	Egr2-independent, Klf1-mediated induction of PD-L1 in CD4+ T cells. Scientific Reports, 2018, 8, 7021.	1.6	10
255	Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia. Oncology Research and Treatment, 2018, 41, 306-312.	0.8	71
256	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocrine Connections, 2018, 7, R196-R211.	0.8	10
257	Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1301-1308.	1.2	12
258	Molecular mechanisms of viral oncogenesis in humans. Nature Reviews Microbiology, 2018, 16, 684-698.	13.6	156
259	Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy. Case Reports in Oncology, 2018, 11, 467-475.	0.3	12
260	Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights. Journal of Comparative Effectiveness Research, 2018, 7, 881-890.	0.6	6
261	Immunotherapy in Merkel cell carcinoma: role of Avelumab. ImmunoTargets and Therapy, 2018, Volume 7, 15-19.	2.7	13
262	Drug response to PD-1/PD-L1 blockade: based on biomarkers. OncoTargets and Therapy, 2018, Volume 11, 4673-4683.	1.0	55
263	Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut, 2018, 67, 2056-2067.	6.1	179
264	PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report. BMC Nephrology, 2018, 19, 210.	0.8	30
265	Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma. International Journal of Biological Markers, 2018, 33, 507-513.	0.7	15
266	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Current Opinion in Pharmacology, 2018, 41, 114-121.	1.7	97
267	Immune-Related Adverse Toxicities and Clinical Management. , 2018, , 577-589.		0
268	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 742-774.	2.3	202
269	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. Mayo Clinic Proceedings, 2018, 93, 917-936.	1.4	4

#	ARTICLE	IF	CITATIONS
270	Carcinoma neuroendocrino cutáneo primitivo. EMC - Dermatología, 2018, 52, 1-13.	0.1	0
271	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clinical Pharmacology and Therapeutics, 2019, 105, 582-597.	2.3	8
272	Functional genomics: paving the way for more successful cancer immunotherapy. Briefings in Functional Genomics, 2019, 18, 86-98.	1.3	6
273	Acquired resistance to cancer immunotherapy. Seminars in Immunopathology, 2019, 41, 31-40.	2.8	34
274	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treatment Reviews, 2019, 74, 49-60.	3.4	38
275	Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clinical Cancer Research, 2019, 25, 1185-1195.	3.2	97
277	Modulating T-cell-based cancer immunotherapy via particulate systems. Journal of Drug Targeting, 2019, 27, 145-163.	2.1	10
278	Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Advances in Therapy, 2019, 36, 2327-2341.	1.3	8
279	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences, 2019, 20, 3821.	1.8	116
280	Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head and Neck, 2019, 41, 4036-4050.	0.9	3
281	Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma. Case Reports in Oncology, 2019, 12, 639-643.	0.3	10
282	A tumor-targeted immune checkpoint blocker. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15889-15894.	3.3	21
283	Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opinion on Biological Therapy, 2019, 19, 1165-1172.	1.4	40
285	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1195.	3.4	431
286	Cutaneous Scapular Lesion in an Elderly Woman. JAMA Oncology, 2019, 5, 1355.	3.4	2
287	Design, Synthesis, Evaluation, and Structural Studies of C ₂ -Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 7250-7263.	2.9	71
288	Complete response with neoadjuvant avelumab in Merkel cell carcinoma – A case report. Oral Oncology, 2019, 99, 104350.	0.8	6
289	Squamous cell carcinoma and Merkel-cell carcinoma. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Przegląd Dermatologiczny, 2019, 106, 127-149.	0.0	2

#	ARTICLE	IF	CITATIONS
290	Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. , 2019, 7, 165.		135
291	Merkel cell carcinoma: a prompt diagnosis to increase survival. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e478-e480.	1.3	0
292	The Mechanism of Anti-“PD-L1 Antibody Efficacy against PD-L1-“Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. Cancer Discovery, 2019, 9, 1422-1437.	7.7	210
293	Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?. Annals of Oncology, 2019, 30, 1667-1668.	0.6	10
294	Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer. Frontiers in Medicine, 2019, 6, 160.	1.2	27
295	Histogenesis of Merkel Cell Carcinoma: A Comprehensive Review. Frontiers in Oncology, 2019, 9, 451.	1.3	63
296	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surgical Oncology Clinics of North America, 2019, 28, 369-386.	0.6	19
297	Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma. Value in Health, 2019, 22, 1170-1177.	0.1	2
298	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987554.	1.4	21
299	Monoclonal Antibodies in Dermatooncology-“State of the Art and Future Perspectives. Cancers, 2019, 11, 1420.	1.7	9
300	Merkel Cell Carcinoma -“ Current Controversies and Future Directions. Clinical Oncology, 2019, 31, 789-796.	0.6	15
301	The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1692-1700.	2.2	193
302	Management of regional metastatic disease in cutaneous malignancy of the head and neck. 3. Merkel cell carcinoma. British Journal of Oral and Maxillofacial Surgery, 2019, 57, 847-856.	0.4	4
303	Advances in Engineering Cells for Cancer Immunotherapy. Theranostics, 2019, 9, 7889-7905.	4.6	44
304	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies, 2019, 8, 51.	1.2	32
305	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94
306	Toll-“like receptors: The role in bladder cancer development, progression and immunotherapy. Scandinavian Journal of Immunology, 2019, 90, e12818.	1.3	46
307	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Journal of Hematology and Oncology, 2019, 12, 92.	6.9	485

#	ARTICLE	IF	CITATIONS
308	Updates on Merkel Cell Carcinoma. <i>Dermatologic Clinics</i> , 2019, 37, 489-503.	1.0	23
310	Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma. <i>Cellular Immunology</i> , 2019, 344, 103961.	1.4	15
311	Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 977-983.	0.6	8
312	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4705.	1.8	48
313	The impact of facility characteristics on Merkel cell carcinoma outcomes: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2023, 89, 70-80.	0.6	10
314	Evaluation of the potential for QTc prolongation with avelumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1017-1026.	1.1	2
315	An update on diagnostic features of Merkel cell carcinoma. <i>Diagnostic Histopathology</i> , 2019, 25, 110-119.	0.2	0
316	Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. <i>Nuclear Medicine and Biology</i> , 2019, 68-69, 66-79.	0.3	19
317	Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. <i>PharmacoEconomics - Open</i> , 2019, 3, 377-390.	0.9	20
318	Características clínico-epidemiológicas del carcinoma de células de Merkel en una serie de 38 pacientes. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 360-365.	0.2	6
319	Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. <i>Immunotherapy</i> , 2019, 11, 429-441.	1.0	44
322	<sc>PD</sc>1, <sc>RB</sc>1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix. <i>Histopathology</i> , 2019, 74, 997-1004.	1.6	27
323	T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins. <i>Antibody Therapeutics</i> , 2019, 2, 22-32.	1.2	12
324	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. <i>Clinical Science</i> , 2019, 133, 181-193.	1.8	51
325	Immunohistochemistry-Enabled Precision Medicine. <i>Cancer Treatment and Research</i> , 2019, 178, 111-135.	0.2	5
327	Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1-21.	0.6	33
328	Checkpoint Inhibitors. <i>Deutsches A&#x0308;rzteblatt International</i> , 2019, 116, 119-126.	0.6	83
329	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333

#	ARTICLE	IF	CITATIONS
330	S2k Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) â€“ Update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 562-577.	0.4	13
331	Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?. , 2019, 7, 141.		14
332	Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget, 2019, 10, 17-29.	0.8	21
333	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. Journal of Hematology and Oncology, 2019, 12, 54.	6.9	416
334	Phase II study of avelumab in multiple relapsed/refractory germ cell cancer. Investigational New Drugs, 2019, 37, 748-754.	1.2	48
335	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 255.	3.5	577
336	Molecular and immune targets for Merkel cell carcinoma therapy and prevention. Molecular Carcinogenesis, 2019, 58, 1602-1611.	1.3	5
338	Immunotherapy in Nonmelanoma Skin Cancer. Actas Dermo-sifiliogrÃ¡ficas, 2019, 110, 353-359.	0.2	1
339	The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.		66
340	S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) â€“ update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 562-576.	0.4	27
341	Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology, 2019, 19, 587-594.	0.5	62
342	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
343	Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal of Gastroenterology, 2019, 54, 538-545.	0.6	51
344	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology, 2019, 16, 563-580.	12.5	1,235
345	Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis. Progress in Retinal and Eye Research, 2019, 72, 100761.	7.3	37
346	Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. Trends in Cancer, 2019, 5, 208-232.	3.8	54
347	Deciphering the universe of genetic context-dependencies using mouse models of cancer. Current Opinion in Genetics and Development, 2019, 54, 97-104.	1.5	3
348	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459

#	ARTICLE	IF	CITATIONS
349	Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106.		203
350	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	3.4	526
351	Sentinel lymph node biopsy in clinically node-negative Merkel cell carcinoma: the Westmead Hospital experience. ANZ Journal of Surgery, 2019, 89, 520-523.	0.3	6
352	Clinical and Epidemiological Characteristics of Merkel Cell Carcinoma in a Series of 38 Patients. Actas Dermo-sifiligráficas, 2019, 110, 360-365.	0.2	0
353	A case of merkel leptomeningeal evolution after complete remission upon anti-PD-1 treatment. European Journal of Cancer, 2019, 113, 55-57.	1.3	2
354	Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 973-982.	2.0	21
355	Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 415-427.	1.3	53
356	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Advances in Cancer Research, 2019, 143, 63-144.	1.9	52
357	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470.	1.3	28
358	Immunotherapy for Advanced Skin Cancer. Actas Dermo-sifiligráficas, 2019, 110, 53-56.	0.2	0
359	Genomic correlates of response to immune checkpoint blockade. Nature Medicine, 2019, 25, 389-402.	15.2	346
360	Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma. JAMA Dermatology, 2019, 155, 803.	2.0	21
361	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. Frontiers of Medicine, 2019, 13, 438-450.	1.5	32
362	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterology, 2019, 10, 364-371.	0.9	65
364	A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. Clinical Genitourinary Cancer, 2019, 17, e549-e552.	0.9	5
365	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Hormone and Metabolic Research, 2019, 51, 145-156.	0.7	234
366	Merkel cell carcinoma metastatic to cervical lymph node in a patient with rheumatoid arthritis: a case report. OncoTargets and Therapy, 2019, Volume 12, 1395-1400.	1.0	0
367	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunology, Immunotherapy, 2019, 68, 917-926.	2.0	59

#	ARTICLE	IF	CITATIONS
368	Risk of immune-related pneumonitis for PD-1/PD-L1 inhibitors: Systematic review and network meta-analysis. <i>Cancer Medicine</i> , 2019, 8, 2664-2674.	1.3	26
369	Combined Inhibition of TGF- β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. <i>Cells</i> , 2019, 8, 320.	1.8	82
370	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
371	PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters. <i>Modern Pathology</i> , 2019, 32, 1359-1372.	2.9	19
372	An Unusual Presentation of Merkel Cell Carcinoma in a HIV Patient: A Case Report and Literature Review. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019, 7, 232470961983669.	0.3	6
373	A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 491.	2.2	23
374	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	0.8	274
375	Characterizing the Therapeutic Potential of a Potent BET Degradator in Merkel Cell Carcinoma. <i>Neoplasia</i> , 2019, 21, 322-330.	2.3	10
376	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
377	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	1.2	11
378	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 609-618.	2.0	21
379	Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 20.	1.3	18
380	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	13.9	1,824
381	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 396-416.	3.6	66
382	A review of avelumab in locally advanced and metastatic bladder cancer. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882348.	0.9	15
383	Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. , 2019, 7, 31.		94
384	Unknown primary Merkel cell carcinoma responding well to first-line treatment with avelumab. <i>Journal of Dermatology</i> , 2019, 46, e273-e275.	0.6	1
385	New perspectives in Merkel cell carcinoma. <i>Current Opinion in Oncology</i> , 2019, 31, 72-83.	1.1	10

#	ARTICLE	IF	CITATIONS
386	Inâ€transit recurrence of Merkel cell carcinoma associated with Bowen's disease: The first reported case successfully treated by avelumab. <i>Journal of Dermatology</i> , 2019, 46, 440-443.	0.6	0
387	B7-H3 Expression in Merkel Cell Carcinomaâ€Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. <i>Clinical Cancer Research</i> , 2019, 25, 3455-3467.	3.2	24
388	Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies. <i>Dermatology and Therapy</i> , 2019, 9, 209-222.	1.4	54
389	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. <i>Clinical Pharmacokinetics</i> , 2019, 58, 835-857.	1.6	222
390	Is it true that gut microbiota is considered as panacea in cancer therapy?. <i>Journal of Cellular Physiology</i> , 2019, 234, 14941-14950.	2.0	27
391	PDâ€1/PDâ€L1 pathway: Basic biology and role in cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 16824-16837.	2.0	279
392	Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 391-407.	3.3	35
393	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. <i>Acta OncolÃ³gica</i> , 2019, 58, 1-8.	0.8	14
394	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 421-432.	1.4	45
395	Augmenting the synergies of chemotherapy and immunotherapy through drug delivery. <i>Acta Biomaterialia</i> , 2019, 88, 1-14.	4.1	29
396	Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 42-45.	0.9	10
397	Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, S585-S588.	0.4	1
398	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 1375-1383.	1.9	22
399	Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma. <i>BMJ Case Reports</i> , 2019, 12, e230518.	0.2	4
400	Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150924.	0.7	1
401	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0
402	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2019, 629, xxi-xl.	0.4	1
403	Heart Block Caused by Cardiac Metastasis From Merkel Cell Carcinoma: A Case Report. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 510-516.	1.2	2

#	ARTICLE	IF	CITATIONS
404	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. <i>Immuno-Oncology Technology</i> , 2019, 4, 1-7.	0.2	2
406	PD-L1 Detection—Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. <i>American Journal of Dermatopathology</i> , 2019, 41, 539-565.	0.3	8
407	Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications. <i>American Journal of Dermatopathology</i> , 2019, 41, 819-825.	0.3	7
408	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5961-5971.	3.2	118
409	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. <i>Current Opinion in Neurology</i> , 2019, 32, 500-510.	1.8	57
410	Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 82-88.	0.6	39
411	Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer. <i>Medicine (United States)</i> , 2019, 98, e16324.	0.4	2
412	Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. <i>Pancreas</i> , 2019, 48, 1111-1118.	0.5	11
413	The Effect of Time to Postoperative Radiation Therapy on Survival in Resected Merkel Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 636-642.	0.6	8
414	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. <i>Oncologist</i> , 2019, 24, 735-742.	1.9	43
415	Immune Checkpoints. , 2019, , 19-43.		0
416	The Current Status of Immunotherapy in Thoracic Malignancies. , 2019, , 45-75.		0
417	Cancers of the Head and Neck. , 2019, , 103-114.		0
418	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). <i>Neuroendocrinology</i> , 2019, 108, 54-62.	1.2	62
419	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
420	Epidemiology of Merkel cell carcinoma. A population-based study from 1985 to 2013, in northeastern of France. <i>International Journal of Cancer</i> , 2019, 144, 741-745.	2.3	29
421	Monitoring response of advanced Merkel cell carcinoma to Avelumab with 18F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1197-1198.	3.3	6
422	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-36.	1.3	31

#	ARTICLE	IF	CITATIONS
423	Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study. <i>Value in Health</i> , 2019, 22, 276-283.	0.1	43
424	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	3.3	53
425	Polyomaviruses of the skin: integrating molecular and clinical advances in an emerging class of viruses. <i>British Journal of Dermatology</i> , 2019, 180, 1302-1311.	1.4	21
426	Expression of Notch 3 and Jagged 1 Is Associated With Merkel Cell Polyomavirus Status and Prognosis in Merkel Cell Carcinoma. <i>Anticancer Research</i> , 2019, 39, 319-329.	0.5	10
427	JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. <i>Future Oncology</i> , 2019, 15, 687-694.	1.1	41
428	Merkel Cell Carcinoma Review. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 39-52.	0.9	39
429	The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. <i>Oncolmmunology</i> , 2019, 8, e1532764.	2.1	30
430	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	1.4	50
431	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and real-life analysis of three larger gene panels. <i>International Journal of Cancer</i> , 2019, 144, 2303-2312.	2.3	95
432	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 106-114.	1.3	41
433	Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. <i>European Journal of Cancer</i> , 2019, 106, 1-11.	1.3	37
434	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 463-474.	1.4	16
435	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 429-443.	1.2	13
436	VEGF-A Inhibition as a Potential Therapeutic Approach in Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 736-739.	0.3	8
437	Radiotherapy and immunotherapy: a synergistic effect in cancer care. <i>Medical Journal of Australia</i> , 2019, 210, 47-53.	0.8	53
438	APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. <i>Oncolmmunology</i> , 2019, 8, 1550341.	2.1	60
439	Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma. <i>Clinical Chemistry</i> , 2019, 65, 462-472.	1.5	24
440	Engineering Precision Medicine. <i>Advanced Science</i> , 2019, 6, 1801039.	5.6	55

#	ARTICLE	IF	CITATIONS
441	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4
442	Predictive Biomarkers and Targeted Therapies in the Skin. , 2019, , 463-474.		0
443	Merkel Cell Carcinoma in the HIV-1/AIDS Patient. Cancer Treatment and Research, 2019, 177, 211-229.	0.2	11
444	HIV/AIDS-Associated Viral Oncogenesis. Cancer Treatment and Research, 2019, , .	0.2	0
445	Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?. Annals of Surgical Oncology, 2019, 26, 315-317.	0.7	4
446	Recurrent Merkel cell carcinoma of the gluteal region: A case report. Dermatologic Therapy, 2019, 32, e12749.	0.8	4
447	Size matters: Dissecting key parameters for panelâ€­based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	2.3	131
448	Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma. Human Pathology, 2019, 84, 52-61.	1.1	23
449	FcÎ³R interaction is not required for effective antiâ€­PDâ€­L1 immunotherapy but can add additional benefit depending on the tumor model. International Journal of Cancer, 2019, 144, 345-354.	2.3	12
450	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
451	FR-Inmunoterapia en el cÃ¡ncer cutÃ¡neo avanzado. Actas Dermo-sifiligrÃ¡ficas, 2019, 110, 53-56.	0.2	1
452	Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. Journal of the American Academy of Dermatology, 2020, 82, 440-459.	0.6	37
453	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. Gastric Cancer, 2020, 23, 133-141.	2.7	15
454	The Landmark Series: Non-melanoma Skin Cancers. Annals of Surgical Oncology, 2020, 27, 22-27.	0.7	13
455	Changing Body Weightâ€­Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. Clinical Pharmacology and Therapeutics, 2020, 107, 588-596.	2.3	33
456	Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. Radiotherapy and Oncology, 2020, 142, 79-84.	0.3	37
457	Angiosarcoma in Collision With a Merkel Cell Carcinoma: Case Report and Literature Review. International Journal of Surgical Pathology, 2020, 28, 325-329.	0.4	1
458	Current Development of Monoclonal Antibodies in Cancer Therapy. Recent Results in Cancer Research, 2020, 214, 1-70.	1.8	16

#	ARTICLE	IF	CITATIONS
459	Diagnosis and Management of Rare Immune-Related Adverse Events. <i>Oncologist</i> , 2020, 25, 6-14.	1.9	31
460	Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma. <i>Modern Pathology</i> , 2020, 33, 42-55.	2.9	30
462	The renal adverse effects of cancer immunotherapy. <i>Journal of Nephrology</i> , 2020, 33, 467-481.	0.9	6
463	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. <i>Seminars in Cancer Biology</i> , 2020, 65, 51-64.	4.3	63
464	Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance. <i>Cancer Medicine</i> , 2020, 9, 1374-1382.	1.3	52
465	Merkel cell carcinoma update: the case for two tumours. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1425-1431.	1.3	19
466	Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. , 2020, 207, 107456.		42
467	Nonmelanoma Skin Cancers. , 2020, , 1052-1073.e8.		1
468	Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 17-22.	0.6	4
469	Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients. <i>Endocrine Pathology</i> , 2020, 31, 21-32.	5.2	28
470	Biomarkers that may predict response to immunotherapy in ovarian malignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 84-90.	0.9	8
471	Biomarkers for Response to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2020, 4, 331-351.	2.3	29
472	New insight in endocrine-related adverse events associated to immune checkpoint blockade. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101370.	2.2	60
473	Expression of Connexin 43 in 32 Cases of Merkel Cell Carcinoma. <i>American Journal of Dermatopathology</i> , 2020, 42, 178-185.	0.3	3
474	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
475	Passive Monoclonal and Polyclonal Antibody Therapies. , 2020, , 251-348.		9
476	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	3.2	70
477	Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice. <i>Journal of Controlled Release</i> , 2020, 317, 282-290.	4.8	3

#	ARTICLE	IF	CITATIONS
478	Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. , 2020, 8, e001076.		18
480	Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma. Future Oncology, 2020, 16, 3021-3034.	1.1	3
481	Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. Transplantation Proceedings, 2020, 52, 2720-2725.	0.3	6
482	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. , 2020, 8, e000897.		40
483	The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events. Immunobiology, 2020, 225, 152009.	0.8	18
484	Using phage-assisted continuous evolution (PACE) to evolve human PD1. Experimental Cell Research, 2020, 396, 112244.	1.2	3
485	Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 1093-1106.	1.1	4
486	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Research, 2020, 30, 364-375.	0.6	42
487	Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment. Cell Reports, 2020, 32, 107873.	2.9	42
488	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resistance Updates, 2020, 53, 100718.	6.5	103
489	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. Frontiers in Oncology, 2020, 10, 549168.	1.3	9
490	<p>Nanomaterial-Based Tumor Photothermal Immunotherapy</p>. International Journal of Nanomedicine, 2020, Volume 15, 9159-9180.	3.3	104
491	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (donâ€™t) know. Journal of Experimental and Clinical Cancer Research, 2020, 39, 236.	3.5	44
492	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 36.	1.0	26
493	Non-Melanoma Skin Cancers: Biological and Clinical Features. International Journal of Molecular Sciences, 2020, 21, 5394.	1.8	83
494	Reply to: Problems With the Recommendations for PD-L1 Biomarker Testing. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, e65-e67.	0.6	0
495	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Frontiers in Cell and Developmental Biology, 2020, 8, 672.	1.8	205
496	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatmentâ€™Current Progress, Strategy, and Future Perspective. Frontiers in Immunology, 2020, 11, 1508.	2.2	60

#	ARTICLE	IF	CITATIONS
497	Somatostatin Receptors in Merkel-Cell Carcinoma: A Therapeutic Opportunity Using Somatostatin Analog Alone or in Association With Checkpoint Inhibitors Immunotherapy. A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 1073.	1.3	8
498	Atypical patterns of response and progression in the era of immunotherapy combinations. <i>Future Oncology</i> , 2020, 16, 1707-1713.	1.1	11
499	Single administration of avelumab induced a complete response in thyroid transcription factor 1â€­positive combined Merkel cell carcinoma. <i>Journal of Dermatology</i> , 2020, 47, 1317-1321.	0.6	0
500	The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 312-319.	0.7	13
501	Gene expression profile identifies distinct molecular subtypes and potential therapeutic genes in Merkel cell carcinoma. <i>Translational Oncology</i> , 2020, 13, 100816.	1.7	4
502	Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. <i>Journal of Personalized Medicine</i> , 2020, 10, 179.	1.1	41
503	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
504	Tailoring precision immunotherapy: coming to a clinic soon?. <i>ESMO Open</i> , 2020, 5, e000631.	2.0	8
505	Tumor infiltrating lymphocyte grade in Merkel cell carcinoma: relationships with clinical factors and independent prognostic value. <i>Acta OncolÃ³gica</i> , 2020, 59, 1409-1415.	0.8	5
506	Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy. <i>Biomaterials</i> , 2020, 263, 120380.	5.7	11
507	Health-related quality of life trajectory of treatment-naïve patients with Merkel cell carcinoma receiving avelumab. <i>Future Oncology</i> , 2020, 16, 2089-2099.	1.1	2
508	Retrospective Multicenter Analysis of the Outcome of a Re-Induction with Immune Checkpoint Inhibitors in Advanced Merkel Cell Carcinoma. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2202-2207.	0.3	6
509	The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors. <i>Anti-Cancer Drugs</i> , 2020, 31, 799-805.	0.7	13
510	Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. <i>Frontiers in Immunology</i> , 2020, 11, 1986.	2.2	146
511	Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy. <i>Future Oncology</i> , 2020, 16, 2521-2536.	1.1	4
512	The Role of Cell Adhesion Molecule 1 (CADM1) in Cutaneous Malignancies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9732.	1.8	15
513	Immunoglobulins to mitigate paraneoplastic Lambert Eaton Myasthenic Syndrome under checkpoint inhibition in Merkel cell carcinoma. <i>Neurological Research and Practice</i> , 2020, 2, 52.	1.0	13
514	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. <i>Cancers</i> , 2020, 12, 3173.	1.7	36

#	ARTICLE	IF	CITATIONS
515	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. <i>Journal of Thoracic Disease</i> , 2020, 12, 5096-5103.	0.6	0
516	Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative 1 st exon 6 th TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8222.	1.8	4
517	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 568931.	2.2	100
518	Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. <i>Science Advances</i> , 2020, 6, eaaz8985.	4.7	93
519	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313.		54
520	Merkel Cell Carcinoma Treatment in Finland in 1986-2016: A Real-World Data Study. <i>Cancers</i> , 2020, 12, 1224.	1.7	5
521	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. , 2020, 8, e000674.		132
522	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
523	Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 145.	1.0	6
524	Scientifically based combination therapies with immunooncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
525	Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 810-817.	1.9	11
526	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. <i>Journal of Hematology and Oncology</i> , 2020, 13, 47.	6.9	84
527	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. <i>Scientific Reports</i> , 2020, 10, 8867.	1.6	13
528	Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. <i>BMC Medical Research Methodology</i> , 2020, 20, 103.	1.4	10
529	An evaluation of avelumab for the treatment of genitourinary tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 971-979.	1.4	4
530	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
531	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 679-697.	3.7	33
532	Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics. <i>Cell</i> , 2020, 182, 85-97.e16.	13.5	115

#	ARTICLE	IF	CITATIONS
533	Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1677.	1.0	23
534	Merkel Cell Carcinoma of the Head and Neck Compared to Other Anatomical Sites in a Real-World Setting: Importance of Surgical Therapy for Facial Tumors. <i>Facial Plastic Surgery</i> , 2020, 36, 249-254.	0.5	3
535	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020, 13, 457-467.	1.1	11
536	Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas. <i>Scientific Reports</i> , 2020, 10, 9077.	1.6	36
537	Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma. <i>Frontiers in Medicine</i> , 2020, 7, 198.	1.2	4
538	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
539	Decreased survival and increased recurrence in Merkel cell carcinoma significantly linked with immunosuppression. <i>Journal of Surgical Oncology</i> , 2020, 122, 653-659.	0.8	10
540	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
541	Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma. <i>Genome Medicine</i> , 2020, 12, 30.	3.6	71
542	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	0.5	119
543	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
544	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
545	Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 398-407.	1.8	29
547	Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective. <i>Cancers</i> , 2020, 12, 554.	1.7	15
548	<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4585-4593.	0.9	37
549	Article Commentary: Cancer Immunotherapy for the General Surgeon. <i>American Surgeon</i> , 2020, 86, 284-292.	0.4	0
550	Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 587-603.	0.8	3
551	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40

#	ARTICLE	IF	CITATIONS
552	Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 187-193.	1.2	7
553	Avelumab as an Emerging Therapy for Eyelid and Periocular Merkel Cell Carcinoma. <i>International Ophthalmology Clinics</i> , 2020, 60, 91-102.	0.3	6
554	Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. <i>Cancer Science</i> , 2020, 111, 907-923.	1.7	33
555	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. <i>Immunology Letters</i> , 2020, 221, 61-71.	1.1	12
556	Landscape of current and future therapies of Merkel cell carcinoma. <i>Dermatologic Therapy</i> , 2020, 33, e13281.	0.8	0
557	Immunobiology of Merkel cell carcinoma. <i>Current Opinion in Oncology</i> , 2020, 32, 114-121.	1.1	11
558	Normalization Cancer Immunotherapy for Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1134-1142.	0.3	13
559	Dual targeting of TGF- β 2 and PD-L1 via a bifunctional anti-PD-L1/TGF- β 2RII agent: status of preclinical and clinical advances. , 2020, 8, e000433.		166
560	Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. <i>Clinical Imaging</i> , 2020, 63, 35-49.	0.8	3
561	Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas. <i>Modern Pathology</i> , 2020, 33, 1433-1442.	2.9	9
562	Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold. <i>Biomaterials</i> , 2020, 239, 119859.	5.7	82
563	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <i>Oncologist</i> , 2020, 25, 290-300.	1.9	51
564	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1
565	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2257-2267.	3.2	39
566	Advances in nanomaterials for photodynamic therapy applications: Status and challenges. <i>Biomaterials</i> , 2020, 237, 119827.	5.7	484
567	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	3.4	125
568	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
569	An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 664-670.	1.0	4

#	ARTICLE	IF	CITATIONS
570	A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 529.	1.3	8
571	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
573	Artesunate Affects T Antigen Expression and Survival of Virus-Positive Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 919.	1.7	17
574	Talkinâ€™™ Toxins: From Coleyâ€™™s to Modern Cancer Immunotherapy. <i>Toxins</i> , 2020, 12, 241.	1.5	47
575	Polyomavirusâ€™™-Driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. <i>Molecular Carcinogenesis</i> , 2020, 59, 807-821.	1.3	32
576	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2146-2156.e4.	0.3	14
577	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2476-2487.	0.8	152
578	Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas. <i>Cancer Immunology Research</i> , 2020, 8, 648-659.	1.6	28
579	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. <i>JCO Oncology Practice</i> , 2020, 16, 319-325.	1.4	15
580	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , 2020, 12, 832.	1.7	27
581	Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 888.	1.7	8
582	High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma*. <i>British Journal of Dermatology</i> , 2021, 184, 319-327.	1.4	28
583	Primary Parotid Merkel Type Small Cell Neuroendocrine Carcinoma with Oligometastasis to the Brain and Adrenal Gland: Case Report and Review of Literature. <i>Head and Neck Pathology</i> , 2021, 15, 311-318.	1.3	5
584	The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC). <i>Annals of Surgical Oncology</i> , 2021, 28, 1019-1028.	0.7	20
585	Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 312-320.	0.6	17
586	Immunotherapies in cutaneous pathologies: an overview. <i>Drug Discovery Today</i> , 2021, 26, 248-255.	3.2	10
587	Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 330-339.	0.6	29
588	Current concepts and approaches to merkel cell carcinoma. <i>Archives of Dermatological Research</i> , 2021, 313, 129-138.	1.1	7

#	ARTICLE	IF	CITATIONS
589	Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. <i>Future Oncology</i> , 2021, 17, 333-347.	1.1	13
590	Carcinoma de c�lulas de Merkel: estudio descriptivo de 11 casos. <i>Actas Dermo-sifiligr�ficas</i> , 2021, 112, 63-68.	0.2	1
591	Molecular Pathogenesis of Merkel Cell Carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 69-91.	9.6	59
592	The emerging role of immunotherapy for the treatment of sarcoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 730-738.	0.8	16
593	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 223-249.	9.6	956
594	PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1803-1811.	1.2	24
595	Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113001.	2.6	27
596	Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. <i>Journal of Cancer</i> , 2021, 12, 1133-1143.	1.2	14
597	The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1935-1939.	1.4	8
598	Folate hydrolase��1 (FOLH1) is a novel target for antibody��based brachytherapy in Merkel cell carcinoma. <i>Skin Health and Disease</i> , 2021, 1, e9.	0.7	3
599	Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding. <i>Protein Expression and Purification</i> , 2021, 177, 105766.	0.6	7
600	Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study. <i>American Journal of Surgery</i> , 2021, 221, 844-849.	0.9	5
601	Merkel cell carcinoma: A review. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 411-421.	0.7	58
602	Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 311-322.	1.4	10
603	There is still a place for tumour��targeted therapies in Merkel cell carcinoma in the era of immune checkpoint inhibitors. <i>British Journal of Dermatology</i> , 2021, 184, 195-197.	1.4	5
604	Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	7
605	Efficacy evaluation of anticancer agents in single-arm clinical trials: analysis of review reports from Pharmaceuticals and Medical Devices Agency. <i>Acta Oncol��gica</i> , 2021, 60, 143-148.	0.8	1
607	Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. <i>Oncolimmunology</i> , 2021, 10, 1958590.	2.1	16

#	ARTICLE	IF	CITATIONS
608	Review of immune checkpoint inhibitors in immuno-oncology. <i>Advances in Pharmacology</i> , 2021, 91, 111-139.	1.2	43
609	Review of Merkel cell carcinoma “ what is known and unknown. <i>Oncolog-Hematolog Ro</i> , 2021, 2, 20.	0.0	0
610	Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors. , 2021, , 31-47.		0
611	Avelumab. , 2021, , 313-325.		0
612	Merkel Cell Carcinoma: A Description of 11 Cases. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2021, 112, 63-68.	0.2	0
613	Emerging Viral Infections. <i>Updates in Clinical Dermatology</i> , 2021, , 91-110.	0.1	1
614	Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?. <i>Current Treatment Options in Oncology</i> , 2021, 22, 19.	1.3	3
615	Monoclonal Antibodies: A Prospective and Retrospective View. <i>Current Medicinal Chemistry</i> , 2021, 28, 435-471.	1.2	8
616	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. <i>Journal of Translational Medicine</i> , 2021, 19, 70.	1.8	5
617	Immunotherapy for Merkel cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 775-781.	0.8	17
618	Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. <i>JCSM Rapid Communications</i> , 2021, 4, 232-244.	0.6	6
619	Identifying the Key Residues Regulating the Binding between Antibody Avelumab and PD-L1 VIA Molecular Dynamics Simulation. , 2021, , .		1
620	Improved survival in women versus men with merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 321-329.	0.6	26
621	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODICE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021, 53, 318-323.	0.4	14
622	Immunotherapy and predictive immunologic profile: the tip of the iceberg. <i>Medical Oncology</i> , 2021, 38, 51.	1.2	4
623	Î³ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , 2021, 9, 612-623.	1.6	22
624	Cerebral metastasis of Merkel cell carcinoma following resection with negative margins and adjuvant external beam radiation: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 118.	0.4	3
625	Identification ACTA2 and KDR as key proteins for prognosis of PDâ€¹/PDâ€¹ blockade therapy in melanoma. <i>Animal Models and Experimental Medicine</i> , 2021, 4, 138-150.	1.3	4

#	ARTICLE	IF	CITATIONS
626	Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 213-226.	0.7	1
627	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. Nanomaterials, 2021, 11, 661.	1.9	23
628	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. Cancers, 2021, 13, 1052.	1.7	5
629	An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 481-491.	1.4	8
630	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 94, 102168.	3.4	6
631	Therapeutic applications of the cancer immunoediting hypothesis. Seminars in Cancer Biology, 2022, 78, 63-77.	4.3	29
632	Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia. Future Oncology, 2021, 17, 1069-1081.	1.1	5
634	Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. BMC Cancer, 2021, 21, 425.	1.1	16
635	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. Immunotherapy, 2021, 13, 419-432.	1.0	9
636	Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. Liver Cancer, 2021, 10, 249-259.	4.2	49
637	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. Blood Reviews, 2021, 50, 100832.	2.8	5
638	Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. Frontiers in Neurology, 2021, 12, 642800.	1.1	26
639	Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. Lung Cancer, 2021, 154, 92-98.	0.9	3
640	Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 36-49.	0.8	8
641	"Present and future of immunotherapy in Neuroendocrine Tumors". Reviews in Endocrine and Metabolic Disorders, 2021, 22, 615-636.	2.6	21
642	Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. Cancer Immunology, Immunotherapy, 2021, 70, 3313-3322.	2.0	17
643	Clinical impact of immunotherapy in Merkel cell carcinoma patients: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2022, 87, 121-130.	0.6	7
645	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 650292.	1.3	22

#	ARTICLE	IF	CITATIONS
646	How we treat Merkel cell carcinoma: within and beyond current guidelines. <i>Future Oncology</i> , 2021, 17, 1363-1377.	1.1	23
647	Virus-Driven Carcinogenesis. <i>Cancers</i> , 2021, 13, 2625.	1.7	31
648	Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 760-767.	0.9	4
649	GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma. <i>Molecular Cancer</i> , 2021, 20, 80.	7.9	17
650	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2111113.	2.8	17
651	Viruses and Skin Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5399.	1.8	12
652	A cost-effectiveness analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan. <i>Cancer Reports</i> , 2021, 4, e1399.	0.6	6
653	Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. <i>Cancers</i> , 2021, 13, 2448.	1.7	13
654	Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review. <i>Viruses</i> , 2021, 13, 822.	1.5	3
655	Systemic Therapy for Head and Neck Skin Cancers. <i>Face</i> , 2021, 2, 121-130.	0.1	0
656	Valproic Acid-Like Compounds Enhance and Prolong the Radiotherapy Effect on Breast Cancer by Activating and Maintaining Anti-Tumor Immune Function. <i>Frontiers in Immunology</i> , 2021, 12, 646384.	2.2	10
657	Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe. <i>Frontiers in Oncology</i> , 2021, 11, 672021.	1.3	4
658	Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies. <i>International Journal of Cancer</i> , 2021, 149, 1189-1198.	2.3	17
659	Genome profiling of mismatch repair genes in eight types of tumors. <i>Cell Cycle</i> , 2021, 20, 1-16.	1.3	0
660	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	1.8	61
661	New Targeted Therapies and Immunotherapies for Locally Advanced Periocular Malignant Tumours: Towards a New "Eye-Sparing" Paradigm?. <i>Cancers</i> , 2021, 13, 2822.	1.7	7
662	The case of acute psychotic episode treatment in patient with myasthenia gravis. <i>Global Journal of Medical and Clinical Case Reports</i> , 2021, , 063-064.	0.0	0
663	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 641428.	1.3	32

#	ARTICLE	IF	CITATIONS
664	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. International Journal of Molecular Sciences, 2021, 22, 6305.	1.8	20
665	Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy. Biology, 2021, 10, 561.	1.3	5
666	The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells. Avicenna Journal of Medical Biotechnology, 2021, 13, 116-122.	0.2	9
667	Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma. Current Treatment Options in Oncology, 2021, 22, 68.	1.3	17
669	Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. Cancers, 2021, 13, 2858.	1.7	12
670	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Annals of Allergy, Asthma and Immunology, 2021, 126, 630-638.	0.5	23
671	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2021). Tj ETQq0 0.0 rgBT /Overlock 1	1.8	1
672	Complete response of merkel cell carcinoma with brain metastases to pembrolizumab and radiotherapy: A case report. Global Journal of Medical and Clinical Case Reports, 2021, , 059-062.	0.0	1
673	Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report. World Journal of Clinical Cases, 2021, 9, 4829-4836.	0.3	2
674	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. Frontiers in Oncology, 2021, 11, 628324.	1.3	2
675	Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis. Frontiers in Oncology, 2021, 11, 693321.	1.3	16
676	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq1 1 0.784314 rgBT /Overl 32	1.8	1
677	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. Journal of Inflammation Research, 2021, Volume 14, 3077-3088.	1.6	5
678	Merkel cell carcinoma: treatment and outcomes over a 10-year period at a high-volume academic center. International Journal of Dermatology, 2021, , .	0.5	2
679	Recurrence and mortality rates with different treatment approaches of Merkel cell carcinoma: a systematic review and meta-analysis. International Journal of Dermatology, 2021, , .	0.5	6
680	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Frontiers in Pharmacology, 2021, 12, 714483.	1.6	9
681	Neuroendocrine Carcinomas of the Digestive Tract: What Is New?. Cancers, 2021, 13, 3766.	1.7	10
682	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 1244-1256.	0.9	4

#	ARTICLE	IF	CITATIONS
683	Merkel cell carcinoma on the right calf in association with chronic lymphocytic leukemia: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04498.	0.2	1
684	An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response. <i>Cancer Medicine</i> , 2021, 10, 5889-5896.	1.3	10
686	Merkel Cell Carcinoma of the Head and Neck: Epidemiology, Pathogenesis, Current State of Treatment and Future Directions. <i>Cancers</i> , 2021, 13, 3506.	1.7	8
687	T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8679.	1.8	3
688	Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review. <i>International Immunopharmacology</i> , 2021, 97, 107703.	1.7	1
689	Autophagy controls programmed death ligand 1 expression on cancer cells (Review). <i>Biomedical Reports</i> , 2021, 15, 84.	0.9	12
690	COMPREHENSIVE REVIEW ON ETIOPATHOGENESIS, TREATMENT AND EMERGING THERAPIES OF BREAST CANCER. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 20-33.	0.3	0
691	Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 5362-5375.	1.4	17
692	<scp>Real-World</scp> Clinical and Economic Outcomes in Selected <scp>Immune-Related</scp> Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, e2002-e2012.	1.9	11
693	Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. <i>Frontiers in Oncology</i> , 2021, 11, 725549.	1.3	6
694	Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1897-1905.	0.3	6
695	Immunotherapy for Non-melanoma Skin Cancer. <i>Current Oncology Reports</i> , 2021, 23, 125.	1.8	49
696	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. <i>Blood Advances</i> , 2021, 5, 3387-3396.	2.5	17
697	Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?. <i>Frontiers in Oncology</i> , 2021, 11, 739006.	1.3	12
698	The treatment of Merkel cell carcinoma with immune checkpoint inhibitors: implications for patients with rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab037.	0.3	3
699	Impact of Pharmacists on Identification of Immune Checkpoint Inhibitor Toxicities. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	0
700	The Association of Radiation Therapy and Chemotherapy on Overall Survival in Merkel Cell Carcinoma: A Population-Based Analysis. <i>Cureus</i> , 2021, 13, e18276.	0.2	1
701	From Merkel Cell Polyomavirus Infection to Merkel Cell Carcinoma Oncogenesis. <i>Frontiers in Microbiology</i> , 2021, 12, 739695.	1.5	29

#	ARTICLE	IF	CITATIONS
702	Cells to Surgery Quiz: September 2021. <i>Journal of Investigative Dermatology</i> , 2021, 141, e111-e117.	0.3	0
703	Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. <i>Annals of Surgical Oncology</i> , 2022, 29, 415-424.	0.7	4
704	Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10629.	1.8	3
705	Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. <i>Nuclear Medicine and Biology</i> , 2021, 100-101, 4-11.	0.3	6
706	Current strategies for intratumoural immunotherapy â€œ Beyond immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 157, 493-510.	1.3	28
707	Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II. <i>Southern Medical Journal</i> , 2021, 114, 614-619.	0.3	2
709	Efficacy and safety profile of avelumab monotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103464.	2.0	2
710	Immunobiology of Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 561-576.	0.7	5
711	Cutaneous Malignancies of the Head and Neck. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 991-1008.	0.9	0
712	Immune checkpoints and reproductive immunology: Pioneers in the future therapy of infertility related Disorders?. <i>International Immunopharmacology</i> , 2021, 99, 107935.	1.7	19
713	Emerging therapies for rare cutaneous cancers: A systematic review. <i>Cancer Treatment Reviews</i> , 2021, 100, 102266.	3.4	4
714	An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112238.	2.5	7
715	Progress and challenges of immunotherapy in triple-negative breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188593.	3.3	106
716	Ubiquitous Merkel Cell Polyomavirus: Causative Agent of the Rare Merkel Cell Carcinoma. , 2021, , 353-383.		0
717	Phage Display Technology as a Powerful Platform for Antibody Drug Discovery. <i>Viruses</i> , 2021, 13, 178.	1.5	32
718	Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2087-2093.	2.0	29
719	PD-L1 â€œ inhibitors in neuroendocrine neoplasia. <i>Medicine (United States)</i> , 2021, 100, e23835.	0.4	7
720	Immune-Checkpoint Inhibitors in B-Cell Lymphoma. <i>Cancers</i> , 2021, 13, 214.	1.7	29

#	ARTICLE	IF	CITATIONS
721	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	1.7	22
722	Neurological Complications of Immune-Based Therapies. , 2020, , 365-372.		2
723	Skin Neuroendocrine Neoplasms. , 2021, , 335-356.		1
724	Therapeutic Development of Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 619-649.	0.8	15
725	Mechanisms of Resistance to Checkpoint Blockade Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 83-117.	0.8	22
726	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. <i>BioDrugs</i> , 2020, 34, 495-503.	2.2	15
727	Inmunoterapia en c�ncer cut�neo no melanoma. <i>Actas Dermo-sifiligr�ficas</i> , 2019, 110, 353-359.	0.2	4
728	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1239-1253.	0.6	56
729	Merkel cell carcinoma in Taiwan. <i>Medicine (United States)</i> , 2019, 98, e17538.	0.4	6
730	Immune Checkpoint Inhibitors in Transplantation��A Case Series and Comprehensive Review of Current Knowledge. <i>Transplantation</i> , 2021, 105, 67-78.	0.5	21
731	Advanced Merkel cell carcinoma��A focus on medical drug therapy. <i>Dermatologic Therapy</i> , 2020, 33, e13675.	0.8	3
732	Metastatic Merkel-cell carcinoma: the dawn of a new era. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224924.	0.2	2
733	Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma. , 2020, 8, e001679.		13
734	Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	128
735	Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients. <i>American Journal of Case Reports</i> , 2018, 19, 505-511.	0.3	29
736	Avelumab for the treatment of metastatic Merkel cell carcinoma. <i>Drugs of Today</i> , 2017, 53, 377.	0.7	6
737	Neutron Radiation Therapy for Treatment of Refractory Merkel Cell Carcinoma. <i>International Journal of Particle Therapy</i> , 2017, 3, 485-491.	0.9	7
738	Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. <i>Journal of Biological Methods</i> , 2019, 6, e114.	1.0	14

#	ARTICLE	IF	CITATIONS
739	<scp>LSD</scp> 1 inhibition induces differentiation and cell death in Merkel cell carcinoma. <i>EMBO Molecular Medicine</i> , 2020, 12, e12525.	3.3	41
740	Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. <i>European Journal of Dermatology</i> , 2018, 28, 78-81.	0.3	42
741	The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients. <i>Aging</i> , 2021, 13, 2279-2293.	1.4	4
742	Non-circadian aspects of BHLHE40 cellular function in cancer. <i>Genes and Cancer</i> , 2020, 11, 1-19.	0.6	25
743	Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. <i>Oncotarget</i> , 2017, 8, 20558-20571.	0.8	49
744	Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review. <i>Oncotarget</i> , 2017, 8, 57889-57897.	0.8	26
745	Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. <i>Oncotarget</i> , 2017, 8, 79731-79741.	0.8	77
746	Analyses of functions of an anti-PD-L1/TGF β 2 bispecific fusion protein (M7824). <i>Oncotarget</i> , 2017, 8, 75217-75231.	0.8	44
747	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	0.8	29
748	Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. <i>Oncotarget</i> , 2018, 9, 23482-23493.	0.8	17
749	Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab. <i>Oncotarget</i> , 2019, 10, 3302-3311.	0.8	6
750	New drug: Avelumab for Merkel cell carcinoma. <i>Australian Prescriber</i> , 2018, 41, 55.	0.5	3
751	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
752	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 655-670.	1.4	95
753	Skin cancer managementâ€”updates on Merkel cell carcinoma. <i>Annals of Translational Medicine</i> , 2018, 6, 282-282.	0.7	6
754	Infusion-related reactions with administration of avelumab: mild and manageable side effects. <i>Translational Cancer Research</i> , 2017, 6, S1296-S1298.	0.4	4
755	Nanoparticles: Properties and Applications in Cancer Immunotherapy. <i>Current Pharmaceutical Design</i> , 2019, 25, 1962-1979.	0.9	12
756	Targeting PD-L1 Protein: Translation, Modification and Transport. <i>Current Protein and Peptide Science</i> , 2018, 20, 82-91.	0.7	20

#	ARTICLE	IF	CITATIONS
757	PD-L1 Inhibitors for the Treatment of Prostate Cancer. <i>Current Drug Targets</i> , 2020, 21, 1558-1565.	1.0	4
758	Frequency and prognosis of metastasis to liver, lung, bone and brain from Merkel cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1101-1113.	1.1	7
759	Effectiveness of Combined Anti-programmed Death-ligand 1 Therapy and Radiotherapy for Metastatic Merkel Cell Carcinoma: Two Case Reports. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00237.	0.6	1
760	Updates to Clinical Information on Anticancer Immunotherapy. <i>Korean Journal of Clinical Pharmacy</i> , 2018, 28, 65-75.	0.0	3
761	Immunoterapia z uÅ¼yciem przeciwciaÅ, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. <i>Acta Haematologica Polonica</i> , 2018, 49, 207-227.	0.1	5
762	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 9-22.	0.1	10
763	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
764	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
765	Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 190.	1.8	31
766	Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 59-64.	0.6	8
767	A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or <i>POLE&i>-Mutated Metastatic or Unresectable Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1135-1144.	1.3	43
768	Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110229.	1.4	3
769	Cutaneous Melanoma and Other Skin Cancers. <i>UNIPA Springer Series</i> , 2021, , 979-1007.	0.1	0
770	Activation of CascadeâLike Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT. <i>Advanced Healthcare Materials</i> , 2022, 11, e2102080.	3.9	5
771	Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer. <i>Journal of Dermatological Science</i> , 2022, 105, 2-10.	1.0	10
772	Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	3
773	Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma. <i>Nature Biomedical Engineering</i> , 2021, 5, 1274-1287.	11.6	33
774	Merkel cell carcinoma presenting as a malignant pleural effusion postâCOVID â19 hospitalization: A case report and literature review. <i>Diagnostic Cytopathology</i> , 2022, 50, E37-E41.	0.5	4

#	ARTICLE	IF	CITATIONS
775	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction. Acta Biomedica Scientifica, 2021, 6, 146-159.	0.1	0
776	Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients. Scientific Reports, 2021, 11, 20763.	1.6	10
777	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. Targeted Oncology, 2021, 16, 761-771.	1.7	5
778	Immune checkpoint inhibitors for cancer and venous thromboembolic events. European Journal of Cancer, 2021, 158, 99-110.	1.3	35
779	Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open, 2021, 6, 100290.	2.0	28
780	Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer. Biomaterials, 2021, 279, 121182.	5.7	22
781	Carcinome de Merkel : actualit�s physiopathologiques et th�rapeutiques. Oncologie, 2018, 20, 19-26.	0.2	1
782	Neue Arzneimittel 2017. , 2018, , 53-148.		0
783	A Case of Merkel Cell Carcinoma of the Lymph Node in the Parotid Gland with Spontaneous Regression of the Skin Lesion. Practica Otologica, 2018, 111, 571-576.	0.0	0
784	Significance of soluble PD-L1 for malignant tumors. Journal of Translational Science, 2018, 5, .	0.2	0
785	Chemotherapy for Temporal Bone Cancer. , 2018, , 403-410.		0
786	Anticorps monoclonaux en oncologie : d�clencher une r�ponse immunitaire en plus de la r�duction tumorale sp�cifique.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 707-735.	0.0	0
788	Study on the Therapeutic Effect of New Drug Bavencio (Avelumab). Pharmacy Information, 2019, 08, 56-61.	0.1	0
789	Melanom. , 2019, , 45-134.		0
790	Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Malignancies. , 2019, , 261-277.		0
791	Andere Tumoren. , 2019, , 191-239.		0
793	An Unusual Case of Squamoid Eccrine Carcinoma of the Abdominal Wall with Inguinal Nodal Metastases: A Case Report and Review of the Literature. Annals of Colorectal Research, 2019, In Press, .	0.1	0
794	Avelumab in the treatment of patients with merkel cell carcinoma: initial results of early access program in Russia. Malignant Tumours, 2019, 9, 53-58.	0.1	1

#	ARTICLE	IF	CITATIONS
797	Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma. Healthbook TIMES Oncology Hematology, 2019, , 8-11.	0.1	0
798	Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report. Clinical Oncology and Research, 2019, , 1-4.	0.1	0
800	Avelumab, una nueva inmunoterapia para pacientes con carcinoma de c�lulas de Merkel metast�sico. Piel, 2019, 34, 518-519.	0.0	0
802	Paradigms in Cancer Drug Development: A Universe with Many Galaxies. , 2020, , 17-44.		0
804	Avelumab for the treatment of patients with Merkel cell carcinoma. Meditsinskiy Sovet, 2020, , 94-100.	0.1	0
805	Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations. AlĚmanah KliniĚskoj Mediciny, 2020, 48, 125-139.	0.2	1
806	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
807	Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences, 2021, , 129-159.	0.2	0
809	Eyelid and Periocular Cutaneous Carcinomas. , 2020, , 1-38.		0
810	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
811	COST-EFFECTIVENESS ANALYSIS OF AVELUMAB TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA. Voprosy Onkologii, 2020, 66, 109-119.	0.1	0
812	Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. Cancer Cell International, 2021, 21, 589.	1.8	17
813	Effect of SHR-1210 on Cardiac Function in Patients after Esophageal Cancer Operation. Advances in Clinical Medicine, 2019, 09, 33-36.	0.0	0
814	Merkel Cell Polyomavirus and Human Merkel Cell Carcinoma. Recent Results in Cancer Research, 2021, 217, 303-323.	1.8	3
815	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. Onkologie (Czech Republic), 2020, 14, 199-204.	0.0	0
816	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. Anesthesia and Analgesia, 2021, 132, 374-383.	1.1	8
817	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting. Journal of Clinical and Aesthetic Dermatology, 2017, 10, S8-S41.	0.1	2
820	A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open, 2021, 7, .	0.4	3

#	ARTICLE	IF	CITATIONS
821	Biomarker-Driven Prognostication in Merkel Cell Carcinoma: A Paradigm for Personalized Therapy. <i>Annals of Surgical Oncology</i> , 2021, , 1.	0.7	1
822	Immune activity in Merkel cell carcinoma. <i>Journal of Dermatology</i> , 2021, 49, 68.	0.6	2
823	Postoperative radiotherapy in stage III Merkel cell carcinoma. <i>Radiotherapy and Oncology</i> , 2022, 166, 203-211.	0.3	2
824	Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 385-395.	1.4	5
825	Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. , 2021, 9, e002996.		24
826	An Extremely Rare Case of Metastatic Merkel Carcinoma of the Liver. <i>Cureus</i> , 2021, 13, e19659.	0.2	0
827	Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 40, 102492.	1.7	4
829	Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1897-1908.	2.0	12
830	Immunotherapy in skin cancers - A narrative review. <i>Journal of Skin and Sexually Transmitted Diseases</i> , 0, .	0.0	0
831	Avelumab in locally advanced or metastatic urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, , .	1.1	1
832	TGF β 2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 763877.	2.2	5
833	PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. <i>International Immunopharmacology</i> , 2022, 103, 108484.	1.7	2
834	Merkel cell polyomavirus and associated Merkel cell carcinoma. <i>Tumour Virus Research</i> , 2022, 13, 200232.	1.5	12
835	Breast Cancer Immunotherapy: From Biology to Current Clinical Applications. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 113-124.	3.0	2
836	Immunotherapy of cancer in the era of checkpoint inhibitor. <i>Clinical and Experimental Metastasis</i> , 2021, 39, 231.	1.7	1
837	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. <i>Journal of Hematology and Oncology</i> , 2022, 15, 6.	6.9	17
838	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
839	Renal cell carcinoma and viral infections: A dangerous relationship?. <i>World Journal of Nephrology</i> , 2022, 11, 1-12.	0.8	1

#	ARTICLE	IF	CITATIONS
840	Emerging strategies for biomaterial-assisted cancer immunotherapy. <i>Korean Journal of Chemical Engineering</i> , 2022, 39, 227-240.	1.2	1
841	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 198-209.	1.9	18
842	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
843	Tertiary Lymphoid Structures and Chemokine Landscape in Virus-Positive and Virus-Negative Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 811586.	1.3	6
844	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective. <i>Frontiers in Oncology</i> , 2022, 12, 780716.	1.3	4
845	Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2022, 28, 2211-2220.	3.2	23
846	Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma. <i>Internal Medicine</i> , 2022, , .	0.3	1
847	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. , 2022, 10, e003302.		16
848	Modelâ€informed drug development supporting the approval of the avelumab flatâ€dose regimen in patients with advanced renal cell carcinoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 458-468.	1.3	5
849	Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, , .	0.5	2
850	Merkel Cell Carcinoma of the Left Eyelid with Metastasis to the Left Submandibular Lymph Nodes: A Case Report and Brief Review. <i>Case Reports in Ophthalmological Medicine</i> , 2022, 2022, 1-3.	0.3	1
851	Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3879-3893.	2.9	55
852	Merkel cell carcinoma brain metastasis with radiological findings mimicking primary CNS lymphoma: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 3, .	0.1	1
853	Prognostic Value of Radiotherapy and Chemotherapy in Stage Iâ€III Merkel Cell Carcinoma. <i>Frontiers in Medicine</i> , 2022, 9, 845905.	1.2	2
854	Immunomodulatory Properties of Immune Checkpoint Inhibitorsâ€More than Boosting T-Cell Responses?. <i>Cancers</i> , 2022, 14, 1710.	1.7	13
855	Conditional survival estimates for merkel cell carcinoma reveal the dynamic nature of prognostication. <i>Journal of Surgical Oncology</i> , 2022, 126, 348-355.	0.8	4
856	Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2022, 21, 236-243.	1.0	6
857	Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2485-2495.	2.0	11

#	ARTICLE	IF	CITATIONS
858	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2323-2341.	3.3	48
859	Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018. JAAD International, 2022, 7, 13-21.	1.1	7
860	Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technology Assessment, 2021, 25, 1-228.	1.3	7
861	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers, 2022, 14, 109.	1.7	21
862	Single-Molecule RNA Sequencing Reveals IFN β -Induced Differential Expression of Immune Escape Genes in Merkel Cell Polyomavirus-Positive MCC Cell Lines. Frontiers in Microbiology, 2021, 12, 785662.	1.5	1
863	Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. World Journal of Gastroenterology, 2021, 27, 8123-8137.	1.4	4
864	Two Clinical Cases of Metastatic Merkel Cell Carcinoma Illustrating Avelumab Tolerability in Elderly Patients. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 599-602.	0.1	0
865	Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. Frontiers in Oncology, 2021, 11, 734354.	1.3	17
866	An Unusual Cause of AKI in a Kidney Transplant Patient with Merkel Cell Cancer. Kidney360, 2021, 2, 2040-2041.	0.9	1
867	Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Clinical Cancer Research, 2022, 28, 1363-1371.	3.2	2
868	Subacute sensory neuronopathy associated with Merkel cell carcinoma with unknown primary: a case report with literature review. Journal of Neurology, 2022, , 1.	1.8	2
880	The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab.. , 2022, 5, 31-45.		0
881	Eyelid and Periocular Cutaneous Carcinomas. , 2022, , 5483-5520.		0
882	New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World Journal of Gastroenterology, 2022, 28, 1751-1767.	1.4	8
883	The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials. Critical Reviews in Oncology/Hematology, 2022, 174, 103700.	2.0	6
884	Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma. Radiotherapy and Oncology, 2022, 173, 32-40.	0.3	5
885	Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. , 2022, 10, e004839.		4
886	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. Frontiers in Immunology, 0, 13, .	2.2	3

#	ARTICLE	IF	CITATIONS
887	Nanodrugs Targeting T Cells in Tumor Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
888	Merkel cell carcinoma of the eyelid and periocular region: A review. <i>Saudi Journal of Ophthalmology</i> , 2021, 35, 186.	0.3	4
889	Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. <i>Journal of Clinical Medicine</i> , 2022, 11, 3364.	1.0	20
890	Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-17.	2.0	1
891	Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma. <i>Australasian Journal of Dermatology</i> , 2022, 63, .	0.4	3
892	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline "Update 2022. <i>European Journal of Cancer</i> , 2022, 171, 203-231.	1.3	51
893	Merkel cell carcinoma of the anorectum: a case report and review of the literature. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
894	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
895	Pulmonary adverse events following immune checkpoint inhibitors. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 391-398.	1.2	9
896	Targeting the CD47-SIRP α Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils. <i>Cancers</i> , 2022, 14, 3366.	1.7	13
898	Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. <i>Hormone and Metabolic Research</i> , 2022, 54, 795-812.	0.7	1
899	Current insight into the regulation of PD-L1 in cancer. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	23
900	Activation of Oncogenic and Immune-Response Pathways Is Linked to Disease-Specific Survival in Merkel Cell Carcinoma. <i>Cancers</i> , 2022, 14, 3591.	1.7	7
901	A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2022, 45, 299-302.	1.2	13
902	First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. <i>Annals of Oncology</i> , 2022, 33, 1179-1185.	0.6	4
904	Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
905	Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
906	Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. <i>Life</i> , 2022, 12, 1229.	1.1	4

#	ARTICLE	IF	CITATIONS
907	Adverse Renal Effects of Anticancer Immunotherapy: A Review. <i>Cancers</i> , 2022, 14, 4086.	1.7	3
908	Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. , 2022, 10, e004904.		12
909	Molecular and immune targets in cutaneous squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2023, 62, 38-51.	1.3	1
910	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
911	Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer. <i>Cancers</i> , 2022, 14, 3835.	1.7	3
912	Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. <i>Lancet, The</i> , 2022, 400, 1008-1019.	6.3	48
913	Combined treatment with radiotherapy, chemotherapy and avelumab results in regression of metastatic Merkel cell carcinoma and improvement of associated Lambert-Eaton myasthenic syndrome: A case report. <i>Oncology Letters</i> , 2022, 24, .	0.8	4
914	Monoclonal antibodies in cervical malignancy-related HPV. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
915	Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
916	ãf;ãf«ã,±ãf«ç [°] èfžãfãf ^a ã,ãf1/4ãfžã, ã,ãf«ã,1. <i>Skin Cancer</i> , 2022, 37, 79-83.	0.1	1
918	Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 4811.	1.7	1
919	Current In Vitro and In Vivo Models to Study MCPyV-Associated MCC. <i>Viruses</i> , 2022, 14, 2204.	1.5	5
920	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
921	Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives. <i>Cancer Biology and Medicine</i> , 0, , 1-13.	1.4	0
922	PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. , 2022, 10, e004590.		12
924	Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer. , 0, , .		0
925	Best practices in surgical and nonsurgical management of head and neck Merkel cell carcinoma: An update. <i>Molecular Carcinogenesis</i> , 2023, 62, 101-112.	1.3	4
926	Mohs micrographic surgery in rare cutaneous tumors: a retrospective study at a Brazilian tertiary university hospital. <i>Anais Brasileiros De Dermatologia</i> , 2023, 98, 36-46.	0.5	2

#	ARTICLE	IF	CITATIONS
928	Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2023, 9, 40.	3.4	22
929	Merkel Cell Carcinoma of the External Ear: Population-Based Analysis and Survival Outcomes. <i>Cancers</i> , 2022, 14, 5653.	1.7	2
930	Avelumab Plus Talazoparib in Patients With <i>BRCA1/2</i> - or <i>ATM</i> -Altered Advanced Solid Tumors. <i>JAMA Oncology</i> , 2023, 9, 29.	3.4	21
931	A web-based predictive model for overall survival of patients with cutaneous Merkel cell carcinoma: A population-based study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
932	Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. , 2022, 10, e005930.		10
933	Therapeutic Antibodies in Cancer Treatment in the UK. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14589.	1.8	1
934	Pulmonary effects of cancer treatments. , 2022, , 253-264.		0
935	Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives. <i>Cancers</i> , 2023, 15, 103.	1.7	9
936	Resistance to immune checkpoint inhibitors and the tumor microenvironment. <i>Experimental Dermatology</i> , 2023, 32, 240-249.	1.4	5
937	The Current Management of Merkel Carcinoma of the Head and Neck: a Scoping Review. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.3	0
939	Merkel cell carcinoma: a forty-year experience at the Peter MacCallum Cancer Centre. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
940	Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2023, 248, 115064.	2.6	3
941	Current treatments and emerging therapies of human polyomavirus-associated skin diseases: a comprehensive review. <i>International Journal of Dermatology</i> , 2023, 62, 387-396.	0.5	5
942	Tumor immunology. , 2023, , 245-452.		0
943	Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. <i>Cancers</i> , 2023, 15, 852.	1.7	6
945	Emerging therapeutic targets of genitourinary tumors. , 2023, , 181-192.		0
946	Targeting critical pathways in ferroptosis and enhancing antitumor therapy of Platinum drugs for colorectal cancer. <i>Science Progress</i> , 2023, 106, 003685042211471.	1.0	2
947	Manipulation and elimination of circulating tumor cells using multi-responsive nanosheet for malignant tumor therapy. <i>Biomaterials Science</i> , 2023, 11, 2590-2602.	2.6	2

#	ARTICLE	IF	CITATIONS
948	Immunotherapies in rare cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	15
949	An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 2291-2298.	3.2	3
950	An update on Merkel cell carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188880.	3.3	3
951	Immunotherapeutic Approaches in Ovarian Cancer. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1233-1249.	1.0	5
952	BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature. <i>Journal of Investigative Dermatology</i> , 2023, 143, 1178-1186.	0.3	1
953	Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine. <i>Journal of Immunotherapy</i> , 2023, 46, 145-151.	1.2	1
954	Demographic and Clinicopathological Factors as Predictors of Lymph Node Metastasis in Merkel Cell Carcinoma: A Population-Based Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 1813.	1.0	0
955	Immunotherapy of Merkel Cell Carcinoma. , 2023, , 1-22.		0
956	Merkel cell carcinoma: an update. <i>Human Pathology</i> , 2023, 140, 39-52.	1.1	4
957	Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies. <i>Cells</i> , 2023, 12, 841.	1.8	3
958	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
959	S2k Guideline "Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) " Update 2022. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 305-320.	0.4	3
960	S2k "Leitlinie "Merkelzellkarzinom " Update 2022. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 305-317.	0.4	1
961	Adjuvant Radiotherapy for Dissected Parotid Lymph Nodes Containing Merkel Cell Carcinoma from an Unknown Primary Skin Site: 2 Case Reports. <i>American Journal of Case Reports</i> , 0, 24, .	0.3	0
962	Personalized Immuno-Oncology with Immunodeficiency Mouse Models. , 2023, , .		0
964	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. <i>Healthcare (Switzerland)</i> , 2023, 11, 1073.	1.0	0
965	Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit. <i>ESMO Open</i> , 2023, 8, 101209.	2.0	1
966	Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. <i>Cancer Reports</i> , 2023, 6, .	0.6	4

#	ARTICLE	IF	CITATIONS
967	Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
968	Immunotherapy and Cancer Stem Cells. , 2023, , 165-235.		0
972	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
973	Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
977	Principles of Monoclonal and Small Molecular Targeting Agents for Pediatric Cancer Management. , 2023, , 1-19.		0
987	Review of Merkel cell carcinoma with solitary pancreatic metastases mimicking primary neuroendocrine tumor of the pancreas. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
989	The contribution of automated cytometry in immuno-oncology. <i>Methods in Cell Biology</i> , 2023, , .	0.5	0
1000	Polymer-mediated nanoformulations: a promising strategy for cancer immunotherapy. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2024, 397, 1311-1326.	1.4	0
1002	Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. <i>Clinical and Experimental Medicine</i> , 2023, 23, 4297-4322.	1.9	2
1006	Post-transplant Malignancies. , 2023, , 605-614.		0
1010	Expanded Alternatives of CRISPRâ€“Cas9 Applications in Immunotherapy of Colorectal Cancer. <i>Molecular Diagnosis and Therapy</i> , 2024, 28, 69-86.	1.6	0
1012	Nanotechnology Potent Photothermal and Photodynamic Immunotherapies of Cancer. <i>Journal of Medical and Biological Engineering</i> , 0, , .	1.0	0
1027	Tumoren der Haut. , 2024, , 945-962.		0